Treating opioid addiction with opioids: groundbreaking science or absolute chaos?

As the opioid crisis continues to impact communities, developing an effective treatment for opioid addiction is a critical public health challenge. This study aims to explore the use of opioid agonists for the treatment of opioid addiction and examine potential controversies surrounding it.

Treatment of OUD with medication such as Methadone and Buprenorphine has been proven to be effective in the treatment of overdose of opioids. The mechanism of action for these opioid agonists are primarily focused on maintenance of the opioid addiction and detoxification. In the United States Buprenorphine is used for office based treatment, whereas Methadone is provided only in the Opioid usage overdose treatment facility centers.

However, many statistical analyses found that opioid agonist treatment for OUD, can pose a major risk for the public health and safety, potentially causing more harm to the patient than the OUD itself. It is crucial to address the issues of misuse and stigma of medication associated with medication assisted treatment in order to optimize patient care of individuals with OUD.

1. Calcaterra, S. L. et al. Methadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid Addiction. Journal of General Internal Medicine, Vol. 34, no. 6, 6 Feb. 2019, pp. 1039–1042, https://doi.org/10.1007/s11606-018-4801-3.

2. Dever, Jill A. et al. The Medications for Opioid Use Disorder Study: Methods and Initial Outcomes from an 18-Month Study of Patients in Treatment for Opioid Use Disorder. Public Health Reports, 25 Jan. 2024, https://doi.org/10.1177/00333549231222479.

3. Fischer, Benedikt. Heroin-Assisted Treatment (HAT) a Decade Later: A Brief Update on Science and Politics. Journal of Urban Health, Vol. 84, no. 4, 12 June 2007, pp. 552–562, www.ncbi.nlm.nih.gov/pmc/articles/ PMC2219559/. https://doi.org/10.1007/s11524-007-9198-y.

4. «Harm Reduction – the Current Situation in Europe (European Drug Report 2024) https://www.euda.europa.eu/publications/european-drug-report/2024/harm-reduction_en. Accessed 3 July 2024.

5. Krawczyk, Noa. Racial and Ethnic Differences in Opioid Agonist Treatment for Opioid Use Disorder in a U. S. National Sample. Drug and Alcohol Dependence, Vol. 178, Sept. 2017, pp. 512–518, europepmc.org/articles/pmc5557040, https://doi.org/10.1016/j.drugalcdep.017.06.009. Accessed 1 May 2019.

6. Krawczyk, Noa, et al. Recent Modifications to S. Methadone Treatment System Are a Band-Aid – Not Solution – to the Nation’s Broken Opioid Use Disorder Treatment System. Health Affairs Scholar, Vol. 1, no. 1, 20 June 2023, https://doi.org/10.1093/haschl/qxad018.

7. Nielsen, Suzanne, et al. Opioid Agonist Treatment for Patients with Dependence on Prescription Opioids. JAMA, Vol. 317, no. 9, 7 Mar. 2017, p. 967, https://doi.org/10.1001/jama.2017.0001. Accessed 27 Aug. 2019.